Lumos Diagnostics Holdings Ltd Total Liabilities

Latest as of December 2025: AU$15.88 Million AUD ≈ $11.24 Million USD

Lumos Diagnostics Holdings Ltd total liabilities. Based on the latest financial reports, Lumos Diagnostics Holdings Ltd (LDX) has total liabilities worth AU$15.88 Million AUD (≈ $11.24 Million USD) as of December 2025. Total liabilities represent everything the company owes to external parties, combining both current liabilities—like accounts payable, short-term debt, and accrued expenses—and non-current liabilities such as long-term debt, pension obligations, lease liabilities, and deferred tax liabilities. Check Lumos Diagnostics Holdings Ltd liquidity resilience to evaluate the company's liquid asset resilience ratio.

Total Liabilities of Lumos Diagnostics Holdings Ltd (2017–2024)

Total liabilities of Lumos Diagnostics Holdings Ltd from 2017 to 2024. This chart illustrates how Lumos Diagnostics Holdings Ltd's total liabilities have evolved over time, based on quarterly financial data.

Lumos Diagnostics Holdings Ltd Competitors by Total Liabilities

The table below lists competitors of Lumos Diagnostics Holdings Ltd ranked by their total liabilities.

Company Country Total Liabilities
Uniform Industrial Corp
TW:2482
Taiwan NT$270.12 Million
UNIQUE
KLSE:0257
Malaysia RM109.04 Million
Ji-Haw Industrial Co Ltd
TW:3011
Taiwan NT$1.25 Billion
Swiss Properties Invest A/S
CO:SWISS
Denmark Dkr453.51 Million
LightInTheBox Holding Co Ltd ARD
NYSE:LITB
USA $65.74 Million
PanGen Biotech Inc
KQ:222110
Korea ₩2.74 Billion
Goa Carbon Limited
NSE:GOACARBON
India Rs-1.69 Billion
Grandstand Limited
NASDAQ:GRSD
USA $179.78 Million

Liability Composition Analysis (2017–2024)

This chart breaks down Lumos Diagnostics Holdings Ltd's total liabilities into key components over time: long-term debt, short-term debt, other current liabilities, and other non-current liabilities. Toggle between absolute values and percentage view to see how the composition has shifted. For the complete balance sheet picture, see LDX total asset value.

Liquidity & Leverage Metrics

Lumos Diagnostics Holdings Ltd Total Liabilities Ratios Explained

Lumos Diagnostics Holdings Ltd total liabilities ratios compare its liabilities with its current assets, cash and shareholder equity.

Metric Value Description
Current Ratio 0.73 Measures ability to pay short-term obligations (Current Assets ÷ Current Liabilities)
Quick Ratio N/A More stringent measure of short-term liquidity ((Current Assets - Inventory) ÷ Current Liabilities)
Cash Ratio 0.29 Most conservative liquidity measure (Cash & Equivalents ÷ Current Liabilities)
Debt to Equity 3.03 Measures financial leverage (Total Liabilities ÷ Shareholder Equity)
Debt to Assets 0.75 Portion of assets financed with debt (Total Liabilities ÷ Total Assets)

Liability Trends Comparison

This chart compares key liability metrics across different time periods, showing how Lumos Diagnostics Holdings Ltd's debt structure has evolved. The comparison includes total liabilities, long-term debt, and current liabilities.

Annual Total Liabilities for Lumos Diagnostics Holdings Ltd (2017–2024)

The table below shows the annual total liabilities of Lumos Diagnostics Holdings Ltd from 2017 to 2024.

Year Total Liabilities Change
2024-12-31 AU$14.65 Million
≈ $10.37 Million
-25.72%
2023-12-31 AU$19.73 Million
≈ $13.96 Million
+23.92%
2022-12-31 AU$15.92 Million
≈ $11.27 Million
-16.45%
2021-12-31 AU$19.05 Million
≈ $13.48 Million
-52.01%
2020-12-31 AU$39.71 Million
≈ $28.10 Million
+388.81%
2019-12-31 AU$8.12 Million
≈ $5.75 Million
-40.89%
2018-12-31 AU$13.74 Million
≈ $9.72 Million
+132.44%
2017-12-31 AU$5.91 Million
≈ $4.18 Million
--

About Lumos Diagnostics Holdings Ltd

AU:LDX Australia Medical Devices
Market Cap
$39.22 Million
AU$55.43 Million AUD
Market Cap Rank
#22603 Global
#805 in Australia
Share Price
AU$0.06
Change (1 day)
+0.00%
52-Week Range
AU$0.06 - AU$0.32
All Time High
AU$1.22
About

Lumos Diagnostics Holdings Limited develops, manufactures, and commercializes point-of-care diagnostic products for diagnosis and management of infectious diseases in the United States. The company's products include FebriDx, a point-of-care diagnostic test for detecting and differentiating viral and bacterial respiratory infections; and ViraDx, a three-in-one point-of-care test for influenza A, … Read more